Plain-English translation of NCT04468061 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a medication that combines chemotherapy with an antibody designed to find cancer cells—works better when given alone or combined with , an immunotherapy drug that helps your body's immune system attack tumors. The study focuses on a specific type of advanced breast cancer (triple-negative, PD-L1-negative) that has limited treatment options today.
Right now, these medications are only approved for certain patients or after other treatments have failed. This trial wants to see if this medication combination could help patients earlier in their treatment journey, potentially slowing or stopping cancer growth.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication alone or the medication combined with a second drug. Both groups receive injections on a repeating 21-day cycle: injections on days 1 and 8 of each cycle for the first medication, and day 1 for the second medication (if assigned to the combination group). You will have regular clinic visits for blood tests, scans, and physical exams to monitor how well the treatment is working and watch for side effects. You will also need to undergo tumor biopsies before starting treatment and again 3–6 weeks after beginning.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States